NCT05727072

A Study of LY3848575 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, and Pharmacokinetics With Single Intravenous Ascending Doses and Single and Multiple Subcutaneous Doses of LY3848575 in Healthy Participants, Including First-generation Japanese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3848575 when administered either intravenously or subcutaneously in single ascending or multiple doses in healthy non-Japanese and first generation Japanese participants. The study will also assess how fast LY3848575 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 142 days excluding the screening period of 28 days.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3848575	Administered IV.
DRUG	LY3848575	Administered SC.
DRUG	Placebo	Administered IV.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2023-02-10
• Primary completion: 2024-02-19
• Completion: 2024-02-19
• First posted: 2023-02-14
• Last updated: 2024-04-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study